Journal article icon

Journal article

Post-diagnostic statin use and breast cancer-specific mortality: a population-based cohort study

Abstract:
PURPOSE: Statins are the most widely prescribed cholesterol lowering medications and have been associated with both improved and unchanged breast cancer outcomes in previous studies. This study examines the association between the post-diagnostic use of statins and breast cancer outcomes (death and recurrence) in a large, representative sample of New Zealand (NZ) women with breast cancer. METHODS: Women diagnosed with a first primary breast cancer between 2007 and 2016 were identified from four population-based regional NZ breast cancer registries and linked to national pharmaceutical data, hospital discharges, and death records. Cox proportional hazard models were used to estimate the hazard of breast cancer-specific death (BCD) associated with any post-diagnostic statin use. RESULTS: Of the 14,976 women included in analyses, 27% used a statin after diagnosis and the median follow up time was 4.51 years. Statin use (vs non-use) was associated with a statistically significant decreased risk of BCD (adjusted hazard ratio: 0.74; 0.63-0.86). The association was attenuated when considering a subgroup of 'new' statin users (HR: 0.91; 0.69-1.19), however other analyses revealed that the protective effect of statins was more pronounced in estrogen receptor positive patients (HR: 0.77; 0.63-0.94), postmenopausal women (HR: 0.74; 0.63-0.88), and in women with advanced stage disease (HR: 0.65; 0.49-0.84). CONCLUSION: In this study, statin use was associated with a statistically significant decreased risk of breast cancer death, with subgroup analyses revealing a more protective effect in ER+ patients, postmenopausal women, and in women with advanced stage disease. Further research is warranted to determine if these associations are replicated in other clinical settings.
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Files:
Publisher copy:
10.1007/s10549-022-06815-w

Authors

More by this author
Role:
Author
ORCID:
0000-0002-8994-2760
More by this author
Role:
Author
ORCID:
0000-0002-7303-061X
More by this author
Role:
Author
ORCID:
0000-0002-9512-9418
More by this author
Role:
Author
ORCID:
0000-0002-1719-7052
More by this author
Role:
Author
ORCID:
0000-0003-0437-8839


More from this funder
Funder identifier:
10.13039/501100001511
Grant:
1217004


Publisher:
Springer
Journal:
Breast Cancer Research and Treatment More from this journal
Volume:
199
Issue:
1
Pages:
195-206
Publication date:
2023-03-17
DOI:
EISSN:
1573-7217
ISSN:
0167-6806


Language:
English
Keywords:
Pubs id:
1339921
Local pid:
pubs:1339921
Source identifiers:
W4327681995
Deposit date:
2026-05-07
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP